Lanreotide + Pembrolizumab
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroenteropancreatic Neuroendocrine Tumors
Conditions
Gastroenteropancreatic Neuroendocrine Tumors
Trial Timeline
Jul 1, 2017 → Jun 7, 2022
NCT ID
NCT03043664About Lanreotide + Pembrolizumab
Lanreotide + Pembrolizumab is a phase 1/2 stage product being developed by Merck for Gastroenteropancreatic Neuroendocrine Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03043664. Target conditions include Gastroenteropancreatic Neuroendocrine Tumors.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03043664 | Phase 1/2 | Completed |
Competing Products
9 competing products in Gastroenteropancreatic Neuroendocrine Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Lutathera + Gallium 68 Dotatate | Novartis | Phase 1 | 33 |
| Lutathera® | Novartis | Pre-clinical | 23 |
| Pasireotide LAR followed by Pasireotide LAR + Everolimus + Everolimus followed by Pasireotide LAR + Everolimus | Novartis | Phase 1 | 33 |
| Lanreotide Autogel 120 mg + Temozolomide (TMZ) | Ipsen | Phase 2 | 49 |
| satoreotide trizoxetan | Ipsen | Phase 1/2 | 38 |
| Lanreotide autogel | Ipsen | Phase 3 | 74 |